Correction to: “Cardiovascular Safety of Romosozumab vs PTH Analogues for Osteoporosis Treatment: A Propensity-Score-Matched Cohort Study”

• December 17, 2024

Role of Albumin-Corrected Calcium and Calcium-Phosphorus Ratio in Detecting Primary Hyperparathyroidism

• by Ataru Okumura, Tatsuya Bando, Ryosei Ashida, Mitsuhiro Kuno, Naoki Tamaki, Toshihiro Mizuguchi, Issei Uchida, Hiroshi Arima

• April 24, 2026

Artificial Intelligence System for Detecting Multiple Diseases Through Retinal Imaging

• by Xiayin Zhang, Qinyi Li, Yinhao Liang, Chunran Lai, Jiahui Cao, Yangqin Feng, Wenyi Hu, Hongyang Jiang, Chunxin Liu, Feng Zhang, Shan Wang, Ying Fang, Cuomu Duojie, Lumei Hu, Fan Xu, Kaiyi Chi, Miao Lin, Li Li, Yih Chung Tham, Yukun Zhou, Carol Y. Cheung, Xiaohong Yang, Bin Sheng, Zhuoting Zhu, Ching-Yu Cheng, Wing W. Y. Ng, Honghua Yu

• April 28, 2026

Higher Steroid Exposure Linked to Systemic Adverse Events in CRSwNP

Higher annual oral corticosteroid exposure was associated with greater odds of systemic adverse events, with avascular bone necrosis and pneumonia showing dose-dependent associations with cumulative dose and osteoporosis associated with longer annual exposure duration.

• by Andrea Surnit

• June 26, 2026

• 5 min